NCT01863225

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Resverlogix Corp · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.

Conditions

• Dyslipidemia
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	RVX000222	capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
DRUG	Rosuvastatin	20 mg daily, 28-42 days
DRUG	Atorvastatin	40 mg daily, 28-42 days
DRUG	Rosuvastatin	40 mg daily, 28-42 days
DRUG	Atorvastatin	80 mg daily, 28-42 days

Timeline

• Start date: 2013-05-01
• Primary completion: 2013-06-01
• Completion: 2013-06-01
• First posted: 2013-05-27
• Last updated: 2015-05-12

Locations

1 site across 1 country: Australia